ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
4 announcements with these filters
Aurobindo Pharma re-appointed Ernst & Young LLP as Internal Auditors for June 2026 to May 2027. The move ensures continuity in internal audit and governance processes.
Dr. Sanjay Chaturvedi has resigned as CEO of Apitoria Pharma Private Limited, a wholly owned subsidiary of Aurobindo Pharma Limited, effective May 4, 2026. He is leaving to pursue a different opportunity. The company has taken the resignation on record.
Aurobindo Pharma Limited announced that Mr. N. Ravikiran, Chief Business Officer for Emerging Markets and Senior Management Personnel, completed his tenure effective May 1, 2026. This administrative update follows standard SEBI disclosure requirements regarding changes in senior management.
Aurobindo Pharma Limited announced that Mr. N. Ravi Kiran, Chief Business Officer of Emerging Markets, retired from the company. His retirement is effective from the close of business hours on April 30, 2026.